




The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 9.8% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	35,247
Cost of Goods Sold	0
Intangible Assets	32,771
Liabilities, Current	33,281
Liabilities, Non-Current	425
Other Assets	2,173
Other Compr. Net Income	86,548
Other Expenses	-419
Other Liabilities	2,190
Other Net Income	269
Other Revenues	0
Property and Equipment	2,073
Research and Development	30,925
Selling, General and Administrative Expense	21,951

Output Variable	Value in 1000 USD
Assets	72,264
Liabilities	35,896
Expenses	52,457
Revenues	0
Stockholders Equity	36,368
Net Income	-52,188
Comprehensive Net Income	-8,914
BaseVar	123,717
ECR before LimitedLiability	130%
Economic Capital Ratio	253%